[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604629":3},{"organization":4,"armGroups":7,"interventions":38,"overallOfficials":53,"centralContacts":57,"locations":66,"responsibleParty":117,"collaborators":44,"id":119,"slug":120,"hasResults":121,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":127,"sex":128,"minAge":129,"maxAge":130,"enrollmentInfo":131,"targetDuration":44,"studyType":134,"phases":135,"briefSummary":137,"conditions":138,"keywords":44,"overallStatus":69,"whyStopped":44,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":150},{"fullName":5,"class":6},"Eli Lilly and Company","INDUSTRY",[8,14,18,24,28,32,35],{"label":9,"type":10,"description":11,"interventionNames":12},"Part A: LY4064912 (Cohorts 1-6)","EXPERIMENTAL","LY4064912 administered subcutaneously (SC)",[13],"Drug: LY4064912",{"label":15,"type":10,"description":16,"interventionNames":17},"Part A: LY4064912 (Cohort 6a)","LY4064912 administered intravenously (IV)",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"Part A: Placebo","PLACEBO_COMPARATOR","Placebo administered SC and IV",[23],"Drug: Placebo",{"label":25,"type":10,"description":26,"interventionNames":27},"Part B: LY4064912 (Cohorts 7-10)","LY4064912 administered SC",[13],{"label":29,"type":20,"description":30,"interventionNames":31},"Part B: Placebo","Placebo administered SC",[23],{"label":33,"type":10,"description":26,"interventionNames":34},"Part C: LY4064912 (Cohort 11)",[13],{"label":36,"type":10,"description":30,"interventionNames":37},"Part C: Placebo",[23],[39,45,48,51],{"type":40,"name":41,"description":42,"armGroupLabels":43,"otherNames":44},"DRUG","LY4064912","Administered SC",[9,25,33],null,{"type":40,"name":41,"description":46,"armGroupLabels":47,"otherNames":44},"Administered IV",[15],{"type":40,"name":49,"description":42,"armGroupLabels":50,"otherNames":44},"Placebo",[19,29,36],{"type":40,"name":49,"description":46,"armGroupLabels":52,"otherNames":44},[19],[54],{"name":55,"affiliation":5,"role":56},"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC\u002FGMT - 5 hours, EST)","STUDY_DIRECTOR",[58,63],{"name":59,"role":60,"phone":61,"phoneExt":44,"email":62},"Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or","CONTACT","1-317-615-4559","LillyTrials@Lilly.com",{"name":64,"role":60,"phone":44,"phoneExt":44,"email":65},"Physicians interested in becoming principal investigators please contact","clinical_inquiry_hub@lilly.com",[67,87,102],{"facility":68,"status":69,"city":70,"state":71,"zip":72,"country":73,"countryCode":74,"cosmosGeoPoint":75,"geoPoint":80,"contacts":81},"Collaborative Neuroscience Network - CNS","RECRUITING","Los Alamitos","California","90720","United States","US",{"type":76,"coordinates":77},"Point",[78,79],-118.07256,33.80307,{"lat":79,"lon":78},[82,84],{"name":44,"role":60,"phone":83,"phoneExt":44,"email":44},"714-799-7799",{"name":85,"role":86,"phone":44,"phoneExt":44,"email":44},"Steven Reynolds","PRINCIPAL_INVESTIGATOR",{"facility":88,"status":69,"city":89,"state":90,"zip":91,"country":73,"countryCode":74,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"ICON Early Phase Services","San Antonio","Texas","78209",{"type":76,"coordinates":93},[94,95],-98.49363,29.42412,{"lat":95,"lon":94},[98,100],{"name":44,"role":60,"phone":99,"phoneExt":44,"email":44},"210-225-5437",{"name":101,"role":86,"phone":44,"phoneExt":44,"email":44},"Robert Bass",{"facility":103,"status":69,"city":104,"state":44,"zip":105,"country":104,"countryCode":106,"cosmosGeoPoint":107,"geoPoint":111,"contacts":112},"Lilly Centre for Clinical Pharmacology","Singapore","138623","SG",{"type":76,"coordinates":108},[109,110],103.85007,1.28967,{"lat":110,"lon":109},[113,115],{"name":44,"role":60,"phone":114,"phoneExt":44,"email":44},"+65-64139811",{"name":116,"role":86,"phone":44,"phoneExt":44,"email":44},"Jeffer Hann Wei Pang",{"type":118,"investigatorFullName":44,"investigatorTitle":44,"investigatorAffiliation":44,"oldNameTitle":44,"oldOrganization":44},"SPONSOR","100604629","phase-1-a-study-of-ly4064912-in-healthy-participants-and-with-overweight-or-obesity-100604629",false,"NCT07152002","A Study of LY4064912 in Healthy Participants and With Overweight or Obesity","A Phase 1, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4064912 in Healthy Participants and Participants With Overweight or Obesity","YHAA","Inclusion Criteria:\n\n* Age is 21-65 years old at Singapore Sites\n* Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring\n\nPart A: Body Mass Index (BMI) within the range greater than or equal to 21 and less than 30 kilogram per square meter (kg\u002Fm²)\n\nPart B: a BMI greater than or equal to 27 and less than 45 kg\u002Fm²\n\nPart C: a BMI greater than or equal to 21 and less than 35 kg\u002Fm²\n\n* Parts A and C: Participants must weigh 60 kilograms (kg) or more at screening\n* Have had a less than 5% change in body weight for 3 months before screening\n* Safety laboratory tests are within normal reference range\n\nExclusion Criteria:\n\n* Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational product; or of interfering with the interpretation of data\n* Have history of diabetes (except gestational diabetes) or current diagnosis of diabetes (any form), or have HbA1c greater than or equal to 6.5% (48 millimole per mole (mmol\u002Fmol)) at screening\n* Are individuals of childbearing potential (IOCBP).",true,"ALL","18 Years","65 Years",{"count":132,"type":133},144,"ESTIMATED","INTERVENTIONAL",[136],"PHASE1","The purpose of this study is to evaluate how well LY4064912 is tolerated and what side effects may occur in healthy participants and participants with overweight and obesity - global. The study drug will be administered either subcutaneously (SC) (under the skin) or infusion intravenously (IV) (into a vein in the arm).\n\nBlood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.",[139,140],"Overweight or Obesity","Healthy","2026-04-17",{"date":143,"type":144},"2026-04-20","ACTUAL",{"date":146,"type":144},"2025-08-28",{"date":148,"type":133},"2026-11",{"name":5,"class":6},3]